Nuevos descubrimientos en cáncer de endometrio

New insights in endometrial cancer

Researchers at the Instituto de Investigaciones Biomédicas, Alberto Sols, (CSIC-UAM), led by Dr. Gema Moreno-Bueno, explore the different subtypes of endometrial cancer
The work, published in the journal Oncogene, describes the high intratumoral heterogeneity of endometrial cancer and proposes new treatments for the subtype classified as ambiguous
The Dr. Gema Moreno-Bueno's group (UAM-IIBM-FMDA-CIBERONC) has carried out a study on endometrial cancer recently published in Oncogene (Oncogene, 2022 Feb 10 doi: 10.1038/s41388-022-02221-0). This study, carried out by Drs. Alba Mota and Sara S. Oltra, a postdoctoral researcher from AECC, have enabled the high intratumoral heterogeneity present in the different subtypes of endometrial cancer (serous and endometrioid) by whole exome sequencing of various regions of the primary tumor and its paired metastases. This analysis has clarified the different patterns of tumor evolution of endometrial cancer that could be relevant in its metastatic spread and its clinical behavior. Additionally, this study has characterized for the first time the genomic alterations present in a subtype of endometrial cancer known as ambiguous, with an adverse clinical prognosis, also allowing the use of the genomic information obtained to establish a personalized treatment in this tumor subtype, which has been validated in preclinical murine models (or Patient Derived Xenografts). Gema Moreno-Bueno emphasizes that understanding the genetic basis of endometrial cancer is the first step to obtain a personalized treatment for patients with this type of cancer.
A schematic of the genetic analysis carried out in this work is shown in the figure.